Bill Alpert, Barron's

Bill Alpert


Mountain View, CA, United States

Contact Bill

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

  • Barron's
  • Moneyish
  • Financial News

Recent articles by Bill:

Pfizer, Novavax, and Other Covid-19 Vaccine Rivals Race Down the Home Stretch. What to Know.

Updates from various companies developing a Covid-19 vaccine show they are moving along at a rapid pace. → Read More

AstraZeneca’s Vaccine-Trial Pause Won’t Slow Its Rivals

Wednesday’s premarket trading hints that investors are shaking off the fright. → Read More

Bausch Spinoff Plan Could Double Your Money, J.P. Morgan Says

Move would help eye-care business get the higher valuation now enjoyed by Alcon and Cooper. → Read More

BioMarin Stock Slumps After FDA’s Surprise Rejection of a Hemophilia Gene Therapy

Wall Street has largely rated the stock a Buy, so it was blindsided by the decision. → Read More

These Leading U.S. Pot Stocks Could Double, Analyst Says

The cannabis retail market in the U.S. will be five to 10 times the size of Canada’s, an analyst says. → Read More

These Companies Are Seeking a Cure for Sickle Cell. And It’s Just the Beginning for Some Gene Therapy Stocks

Successful treatments would demonstrate the potential for gene therapy—and boost a number of biotech companies. → Read More

Harley-Davidson Is a Buy Because Its Profits Will Grow, Says UBS

Analyst Robin Farley increased her target for the stock price from $24 to $31. → Read More

Aphria Might Be a Bargain Among Marijuana Stocks. One Analyst Explains Why.

Aphria trades at a discount to other pot producers despite better fundamentals. → Read More

These 2 Wireless Stocks Will Benefit From 5G, Bernstein Says

China Mobile and China Tower look like attractive opportunities. → Read More

Harley-Davidson’s New CEO Will Turn It Around, Says Citi

The motorcycle maker’s cheap valuation and its new chief executive make the stock a good bet, a Citi analyst writes. → Read More

Epidemiologists Fear ‘Stuttering, Endless Loop’ of Covid-19 Infections. Watch Out, Investors.

Americans—and investors—should not drop their guard against the coronavirus. → Read More

Moderna Will Start Testing Its Covid-19 Vaccine on 30,000 People in July

The biotech startup Moderna says it will begin the pivotal trial of its candidate vaccine against Covid-19 in July. → Read More

This Summer, Regional Theme Parks, and Their Stocks, Become Fun Again

As theme parks cautiously start reopening this month, regional parks have an edge. → Read More

In a Changed World for Health Insurers, Goldman Sachs Likes UnitedHealth and Humana Stock

Goldman likes the managed care companies that are big and involved with Medicare supplemental insurance. → Read More

Micron Says 5G Phones Will Have Giant Memories, Reports Needham. It Rates the Stock at Buy.

The firm sees 40% upside for the chip maker’s stock. → Read More

Another Biotech Stock Gets a Lift From Encouraging, but Early, Vaccine Data

Inovio, like Moderna, is conducting a Phase 1 human trial of its vaccine, with 40 volunteers enrolled. It plans to report initial results on safety and... → Read More

U.S. Pot Producer Green Thumb Outsells Canada’s Aurora Cannabis

American firms like Green Thumb Industries have outsold Canada’s better known pot companies. → Read More

Gene-Therapy Treatments for Tay-Sachs, Sickle Cell, Other Diseases to Be Featured in Online Gathering

This week’s online annual meeting of the American Society for Gene and Cell Therapy will take place on the web. → Read More

AbbVie Stock Is ‘Unsustainably Cheap’ After Allergen Acquisition

SVBLeerink analyst Geoffrey Porges boosted his price target for AbbVie stock from $107 to $122. → Read More

Marijuana Grower Cronos Crimped by Covid-19

Cronos has never sold much cannabis. That didn’t change in the March quarter. → Read More